BREA, Calif., Nov. 20, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced the release of its 2023 Sustainability Report, outlining its continued efforts to integrate environmental, social, and governance (ESG) considerations into its mission to digitize, personalize, and democratize dental care. The full report can be found HERE."Our efforts to promote improved environment, social, and governance initiatives are central to how we support our stakeholders. Through the lens of our ...

BREA, Calif., Nov. 19, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in a fireside chat at the Evercore HealthCONx Conference on Tuesday, December 3, 2024 from 12:30 – 1:15 pm ET at the Loews Coral Gables Hotel in Coral Gables, Florida. There will be an audio-only recording link that can be viewed on Envista's Investor Relations website for up to 365 days post event.ABOUT ENVISTA HOLDINGS CORPORATIONEnvista is a global family of ...

Financial Data and Key Metrics Changes - Reported sales for Q3 2024 were $601 million, with core sales declining 5.3% year-over-year after adjusting for currency exchange rates [17] - Adjusted gross margin was 52.8%, down 490 basis points compared to the prior year [23] - Adjusted EBITDA margin for the quarter was 9.1%, which is 10.5 percentage points lower than the previous year [23] - Adjusted diluted EPS in Q3 was $0.12, compared to $0.43 in Q3 2023 [23] - Free cash flow for the quarter was $63 million, down from $77 million in Q3 of the previous year, but year-to-date free cash flow was $179 million, up 45% year-over-year [37] Business Line Data and Key Metrics Changes - Specialty products and technology segment saw a core revenue decline of 5.2% year-over-year, with orthodontic business declining low double digits due to Spark revenue deferral impact [30] - Implant growth was flat year-over-year, with North America showing improvement as the gap relative to market continued to close [32] - Equipment and consumables segment core sales decreased by 5.6% year-over-year, with diagnostics business declining mid-single digits, although North America grew for the third consecutive quarter [34] Market Data and Key Metrics Changes - North America business declined mid-single digits, while West Europe declined high single digits [21] - China business declined low double digits, primarily due to weaker diagnostic sales [22] - The overall dental market was generally flat, with some segments like implants showing slight growth [12] Company Strategy and Development Direction - The company reaffirmed its full-year guidance of negative 1% to negative 4% core growth and 10% to 12% adjusted EBITDA margins, expecting a return to growth in Q4 [39] - Focus on rebuilding operational capabilities and improving execution rhythm, with significant investments in leadership and the Envista Business System [41] - Continued commitment to innovation and customer engagement, with various events held to strengthen relationships with clinicians [42] Management's Comments on Operating Environment and Future Outlook - Management noted that while the dental market remains soft, there are early signals of potential improvement, such as decreasing interest rates and high unmet patient demand [47] - The company is focused on systematically improving performance and rebuilding its execution foundation [48] - Long-term outlook for the Chinese market remains positive despite current volatility [80] Other Important Information - The Spark revenue deferral change had a significant impact on Q3 results, with $27 million lower revenue due to this change [18] - The company is actively managing channel inventory, which has resulted in lower revenue but supports a healthier supply chain [20] Q&A Session Summary Question: Can you talk about whether this was a function of markets improving or just cautious execution? - Management indicated that market growth remains slow, and the performance was more about improving execution rather than market conditions [46] Question: Was there any catch-up provisions in the Spark deferral this quarter? - Management confirmed there were no changes in the deferral rate from Q2 to Q3, and the impact was primarily due to timing [65] Question: How do you think about the investments going forward? - Management stated that investments are necessary for growth and will continue into 2025, with a focus on high-return areas [76] Question: What are the areas of strength versus weakness in China? - Management expressed confidence in the long-term potential of the Chinese market, despite current geopolitical and economic volatility [80] Question: Can you provide insights on the implant organization and investments? - Management highlighted that significant investments have been made in commercial activities, which have positively impacted performance in North America [110]

Envista (NVST) reported $601 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 4.8%. EPS of $0.12 for the same period compares to $0.43 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $592.28 million, representing a surprise of +1.47%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being $0.09.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...

Envista (NVST) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this maker of dental products would post earnings of $0.27 per share when it actually produced earnings of $0.11, delivering a surprise of -59.26%.Over the last four quarters, th ...

The market expects Envista (NVST) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

BREA, Calif., Oct. 7, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its third quarter 2024 on Wednesday, October 30, 2024. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the c ...

BREA, Calif., Aug. 27, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the Baird 2024 Global Healthcare Conference on Wednesday, September 11, 2024 from 10:50 – 11:20 am ET at the InterContinental New York Barclay. There will be no recording link available for this event. ABOUT ENVISTA HOLDINGS CORPORATION Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by ...

Did you analyze how Envista (NVST) fared in its international operations for the quarter ending June 2024? Given the widespread global presence of this maker of dental products, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must ...

Envista Holdings Corporation (NVST) reported adjusted earnings per share (EPS) of 11 cents for secondquarter 2024, down 74.4% year over year. The bottom line missed the Zacks Consensus Estimate by 59.3%. The adjustments include a $1.15 billion non-cash charge related to the impairment of goodwill and intangible assets, charges and benefits related to the amortization of acquired intangible assets and restructuring costs, among others. The company's GAAP loss was $6.69 compared with the year-ago quarter's ea ...